Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model

被引：0
|
作者：
Michael Willis
Andreas Nilsson
Klas Kellerborg
Philip Ball
Rupert Roe
Shana Traina
Rebecca Beale
Isabelle Newell
机构：
[1] The Swedish Institute for Health Economics,
[2] Mundibiopharma Limited,undefined
[3] Napp Pharmaceuticals Limited,undefined
[4] Janssen Global Services,undefined
[5] LLC,undefined
[6] Costello Medical Consulting Limited,undefined
来源：
Diabetes Therapy | 2021年 / 12卷
关键词：
Albuminuria; Canagliflozin; Chronic kidney disease (CKD); Cost-effectiveness; CREDENCE; Diabetes; Diabetic kidney disease (DKD); Diabetic nephropathy; Dialysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：313 / 328
页数：15
相关论文
共 50 条
  • [31] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS A DPP-4 INHIBITOR IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A440 - A440
  • [32] COST-EFFECTIVENESS OF FINERENONE IN ADDITION TO STANDARD-OF-CARE IN TREATING TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE IN CHINA
    He, Y.
    Ming, J.
    Chen, J.
    Hong, G.
    Xu, Y.
    Mernagh, P.
    Pochopien, M.
    Li, H.
    VALUE IN HEALTH, 2023, 26 (12) : S103 - S103
  • [33] THE IMPORTANCE OF HBA1C EVOLUTION IN COST-EFFECTIVENESS MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    He, J.
    Neslusan, C.
    Johansen, P.
    Worbes-cerezo, M.
    VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
  • [34] ASSESSMENT OF THE KEY DRIVERS OF COST-EFFECTIVENESS IN THE ECONOMIC MODELLING OF CANAGLIFLOZIN (CANA) VERSUS GLIMEPIRIDE (GLIM) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK SETTING
    Thompson, G.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Schroeder, M.
    Girod, I
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [35] Cost-effectiveness of Finerenone in Addition to Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in China
    Ming, Jian
    Hong, Guanqi
    Xu, Yingrui
    Mernagh, Paul
    Pochopien, Michal
    Li, Hongchao
    ADVANCES IN THERAPY, 2024, 41 (08) : 3138 - 3158
  • [36] ESTIMATED EVENTS AVOIDED AND COST OFFSETS ASSOCIATED WITH USING CANAGLIFLOZIN TO TREAT PATIENTS WITH TYPE TWO DIABETES MELLITUS (T2DM) WITH OR AT HIGH RISK OF DEVELOPING CARDIOVASCULAR DISEASE (CVD) IN ENGLAND
    Sanchez, Garcia J. J.
    Willis, M.
    Nilsson, A.
    Ericson, O.
    Ball, P.
    Dunlop, W.
    VALUE IN HEALTH, 2018, 21 : S127 - S127
  • [37] COST-EFFECTIVENESS OF RANOLAZINE ADDED TO STANDARD OF CARE TREATMENT IN PATIENTS WITH CHRONIC ANGINA AND TYPE 2 DIABETES
    Coleman, Craig I.
    Weeda, Erin R.
    Nguyen, Elaine
    Kohn, Christine
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 204 - 204
  • [38] Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naive Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
    Shafie, Asrul Akmal
    Ng, Chin Hui
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 333 - 343
  • [39] Cost-effectiveness of strict "get to goal" treatment directives in the treatment of younger patients with newly diagnosed type 2 diabetes mellitus (T2DM)
    Willis, M.
    Borg, S.
    Persson, U.
    Neslusan, C.
    VALUE IN HEALTH, 2007, 10 (06) : A260 - A260
  • [40] Real-World Outcomes of Patients with Type 2 Diabetes Mellitus (T2DM) Treated with Canagliflozin in a US Managed Care Setting
    Chow, Wing
    Buysman, Erin K.
    Rupnow, Marcia F. T.
    Henk, Henry J.
    DIABETES, 2015, 64 : A347 - A348
12345